Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY
Total Valuation
Dr Reddy's Laboratories has a market cap or net worth of $12.44B. The enterprise value is $12.38B.
Market Cap$12.44B
Enterprise Value$12.38B
Share Statistics
Dr Reddy's Laboratories has 834,568,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding834,568,240
Owned by Insiders―
Owned by Institutions3.09%
Financial Efficiency
Dr Reddy's Laboratories’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 13.34%.
Return on Equity (ROE)0.17
Return on Assets (ROA)0.11
Return on Invested Capital (ROIC)13.34%
Return on Capital Employed (ROCE)0.20
Revenue Per Employee12.04M
Profits Per Employee2.12M
Employee Count27,048
Asset Turnover0.66
Inventory Turnover1.90
Valuation Ratios
The current PE Ratio of Dr Reddy's Laboratories is 18.4. Dr Reddy's Laboratories’s PEG ratio is ―.
PE Ratio18.4
PS Ratio―
PB Ratio―
Price to Fair Value2.82
Price to FCF―
Price to Operating Cash Flow19.94
PEG Ratio―
Income Statement
In the last 12 months, Dr Reddy's Laboratories had revenue of 325.54B and earned 56.54B in profits. Earnings per share was 67.85.
Revenue325.54B
Gross Profit190.43B
Operating Income71.84B
Pretax Income76.78B
Net Income56.54B
EBITDA96.67B
Earnings Per Share (EPS)67.85
Cash Flow
In the last 12 months, operating cash flow was 46.43B and capital expenditures -34.40B, giving a free cash flow of 12.03B billion.
Operating Cash Flow46.43B
Free Cash Flow12.03B
Free Cash Flow per Share14.41
Dividends & Yields
Dr Reddy's Laboratories pays an annual dividend of $0.091, resulting in a dividend yield of 0.62%
Dividend Per Share$0.091
Dividend Yield0.62%
Payout Ratio11.49%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.48
52-Week Price Change-5.23%
50-Day Moving Average14.32
200-Day Moving Average14.17
Relative Strength Index (RSI)64.91
Average Volume (3m)889.06K
Important Dates
Dr Reddy's Laboratories upcoming earnings date is Oct 24, 2025, Before Open (Confirmed).
Last Earnings DateJul 29, 2025
Next Earnings DateOct 24, 2025
Ex-Dividend DateJul 25, 2025
Financial Position
Dr Reddy's Laboratories as a current ratio of 1.92, with Debt / Equity ratio of 13.90%
Current Ratio1.92
Quick Ratio1.37
Debt to Market Cap0.04
Net Debt to EBITDA0.33
Interest Coverage Ratio25.40
Taxes
In the past 12 months, Dr Reddy's Laboratories has paid 19.54B in taxes.
Income Tax19.54B
Effective Tax Rate0.25
Enterprise Valuation
Dr Reddy's Laboratories EV to EBITDA ratio is 10.06, with an EV/FCF ratio of 80.83.
EV to Sales2.99
EV to EBITDA10.06
EV to Free Cash Flow80.83
EV to Operating Cash Flow20.94
Balance Sheet
Dr Reddy's Laboratories has $57.91B in cash and marketable securities with $46.77B in debt, giving a net cash position of $11.14B billion.
Cash & Marketable Securities$57.91B
Total Debt$46.77B
Net Cash$11.14B
Net Cash Per Share$13.35
Tangible Book Value Per Share$274.27
Margins
Gross margin is 57.65%, with operating margin of 22.07%, and net profit margin of 17.37%.
Gross Margin57.65%
Operating Margin22.07%
Pretax Margin23.59%
Net Profit Margin17.37%
EBITDA Margin29.70%
EBIT Margin24.46%
Analyst Forecast
The average price target for Dr Reddy's Laboratories is $16.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.00
Price Target Upside7.67% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast13.13%
EPS Growth Forecast-0.47%